Analyst: AmSurg going nowhere for now

Cantor Fitzgerald analyst Joe France says investors shouldn't look to AmSurg for price appreciation in the near future. Initiating coverage with a 'hold' rating and a price target of $26, France says "the extent of the market's recovery is unclear" and that CEO Chris Holden and his team have their hands full integrating National Surgical Care. Shares of AmSurg (Ticker: AMSG) closed Monday trading just above $26 and are flat for the year.